SCHEMBL1720545

SCHEMBL1720545

Sc1nnc(SCc2ccccc2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
HPGD P15428 1/20 0.58
ALDH1A1 P00352 4/20 0.55
MAPT P10636 2/20 0.55
FFAR1 O14842 1/20 0.52
MAPK1 P28482 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
CA1 P00915 2/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
GAA P10253 2/20 0.49
PKM P14618 1/20 0.49
TSHR P16473 1/20 0.49
KDM4E B2RXH2 2/20 0.47
RECQL P46063 1/20 0.47
CDK2 P24941 1/20 0.47
ABL1 P00519 3/20 0.46
SRC P12931 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3263155 0.87 LMNA (0.72) LMNAHPGDALDH1A1MAPTFFAR1
SCHEMBL23137230 0.81 LMNA (0.66) LMNAHPGDALDH1A1MAPTFFAR1
SCHEMBL24700466 0.81 LMNA (0.66) LMNAHPGDALDH1A1MAPTFFAR1
SCHEMBL9479429 0.81 LMNA (0.74) LMNAHPGDALDH1A1MAPTFFAR1
SCHEMBL490778 0.79 NPC1 (0.43) LMNAHPGDALDH1A1MAPTFFAR1
SCHEMBL6492979 0.79 MEN1 (0.59) LMNAHPGDALDH1A1MAPTFFAR1
SCHEMBL23137231 0.79 LMNA (0.62) LMNAHPGDALDH1A1MAPTFFAR1
SCHEMBL3906094 0.79 MAPK1 (0.62) LMNAHPGDALDH1A1MAPTFFAR1
SCHEMBL10985991 0.79 NPC1 (0.78) LMNAHPGDALDH1A1MAPTFFAR1
SCHEMBL6097608 0.78 RAB9A (0.50) LMNAHPGDALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113038734-B Organic metal solderability preservative, preparation method and application of organic metal solderability preservative film 广州三孚新材料科技股份有限公司 2022-02-15 CN claimed
CN-113038734-A Organic metal solderability preservative, preparation method and application of organic metal solderability preservative film 广州三孚新材料科技股份有限公司 2021-06-25 CN claimed
CN-113038734-B Organic metal solderability preservative, preparation method and application of organic metal solderability preservative film 广州三孚新材料科技股份有限公司 2022-02-15 CN disclosed
CN-113038734-A Organic metal solderability preservative, preparation method and application of organic metal solderability preservative film 广州三孚新材料科技股份有限公司 2021-06-25 CN disclosed
EP-3130465-B1 HEAT-SENSITIVE LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA NV (BE) 2020-05-13 EP disclosed
EP-3130465-B1 HEAT-SENSITIVE LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA NV (BE) 2020-05-13 EP disclosed
US-20180236759-A1 HEAT-SENSITIVE LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA NV (BE) 2018-08-23 US disclosed
WO-2017025307-A1 HEAT-SENSITIVE LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA GRAPHICS NV (BE) 2017-02-16 WO disclosed
WO-2017025307-A1 HEAT-SENSITIVE LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA GRAPHICS NV (BE) 2017-02-16 WO disclosed
EP-3130465-A1 HEAT-SENSITIVE LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA GRAPHICS NV (BE) 2017-02-15 EP disclosed
EP-3130465-A1 HEAT-SENSITIVE LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA GRAPHICS NV (BE) 2017-02-15 EP disclosed
US-8241740-B2 Layer laminated to support; ionization radiation; curing using free radical catalyst; image display and polarization plates FUJIFILM CORPORATION (JP) 2012-08-14 US disclosed
US-20120168681-A1 Surface Modified Metal Nano-Particle and Use Thereof POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2012-07-05 US disclosed
EP-2452683-A2 Methods for treating atherosclerosis Amgen Inc. (US) 2012-05-16 EP disclosed
EP-2037928-B1 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC (US) 2012-01-11 EP disclosed
US-20110206652-A1 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC. (US) 2011-08-25 US disclosed
EP-2037928-A2 METHODS FOR TREATING ATHEROSCLEROSIS Amgen Inc. (US) 2009-03-25 EP disclosed
US-20080096900-A1 Methods for treating atherosclerosis AMGEN INC. (US) 2008-04-24 US disclosed
WO-2008002591-A2 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC (US) 2008-01-03 WO disclosed
EP-0403100-A2 High sensitivity photopolymerizable compositions containing hydrogen donating mercaptans MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096900-A1 Methods for treating atherosclerosis LCAT, PCSK9, CETP LMNA 535/4885HPGD 1390/4885ALDH1A1 2876/4885
US-20110206652-A1 METHODS FOR TREATING ATHEROSCLEROSIS LCAT, PCSK9, CETP LMNA 535/4885HPGD 1390/4885ALDH1A1 2876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.